June 18, 2018 06:08 AM EDT
R&D

Af­ter a crush­ing PhI­II fail­ure, Cy­to­ki­net­ics says its next-gen mus­cle drug is lin­ing up well in PhII — but big chal­lenges loom

John Carroll

Editor & Founder

For the past 6 months, Cy­to­ki­net­ics $CYTK CEO Robert Blum has been hold­ing things to­geth­er in the wake of a dev­as­tat­ing late-stage dis­as­ter that swept …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times